

Regenosca closes CHF 1M pre-seed round to demonstrate endoscopic delivery of TissueSpan implants

Lausanne, Switzerland - July 22, 2024 - Regenosca creates unique bio-implants, enabling the body to attract and organise its own cells for seamless healing. Providing a temporary, naturally absorbed bridge, the TissueSpan technology replaces diseased tissue and restores patients to full health.

With access to markets worth up to \$5bn annually for Regenosca's regenerative medicine platform, the initial application is urethral stricture (narrowing), affecting up to a million patients a year in the U.S. The current gold-standard procedure involves open surgery and the harvesting of a patient's own inner mouth tissue for grafting. Simpler endoscopic treatments have up to 80% failure rates. The company has already performed human trials with perfect regrowth of the patients' own tissue.

Regenosca has successfully raised CHF 1 million from private investors, Business Angels Switzerland, and Venture Kick. "This funding will allow us to demonstrate endoscopic delivery of TissueSpan", said Eva-Maria Balet, CEO and co-founder. "This new approach will revolutionise the treatment of urethral stricture. An off-the-shelf implant instead of the patient's own tissue. A simple endoscopic procedure instead of complex open surgery."

Prof Philippe Sèbe, urologist at Hôpitaux Universitaires Genève (HUG) and clinical development partner with Regenosca on the endoscopic technology, emphasises: "TissueSpan implants represent a great opportunity, opening up a significant new area of development in urethral repair surgery."

Preclinical data and successful completion of the first human trials show promising market traction, winning awards at the three biggest urology conferences globally: the European Association of Urology, the Société Internationale d'Urologie, and the American Urological Association.

Recognising the generous support received to date from Innosuisse, the Gebert Rüf Foundation, and Venture Kick, Regenosca proudly welcomes this new group of investors.

About:

Regenosca (www.regenosca.com) is a regenerative medtech firm based in Lausanne that provides *seamless tissue regeneration* to solve today's difficult clinical problems in a surgeon- and patient-friendly way.

Contact:

Dr Eva-Maria Balet
+41 78 868 79 73
balet@regenosca.com